Lupin Limited (LUPIN) 12 days ago

Lupin Expands US Product Portfolio

• Key Highlights:
  • Lupin launches Eslicarbazepine Acetate Tablets in the US
  • Estimated annual sales of USD 395 million in the US
  • Eligible for 180-day shared generic exclusivity
  • Global pharmaceutical leader with products in over 100 markets

What This Means for You

This launch is a positive for Lupin, expanding its US presence. However, the large market size may attract competition, potentially impacting Lupin's market share. Monitor the company's performance and US market dynamics.